Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Clin Pharmacol Ther. 2013 Aug;94(2):207-10. doi: 10.1038/clpt.2013.59. Epub 2013 Mar 19.
The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience.
近年来,具有潜在临床意义的药物遗传学变异的发现速度显著加快。然而,将这一新知识应用于个体化患者护理的步伐却较为缓慢。药物基因组学研究网络(PGRN)转化药物遗传学计划旨在确定障碍,并为在不同医疗保健环境中实施基于证据的药物遗传学检测制定切实可行的解决方案。传播由此产生的“实施最佳实践”工具包将对广泛的受众证明是有用的。